Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-3 trial of oral LY4268989 (MORF-057) in adults with moderately to severely active ulcerative colitis
MOH_2026-05-07_015809Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LY4268989 in autoimmune colitis (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Clinical remission at week 10 and Clinical remission at week 52. Started Apr 2026; status: recruiting.
02
Drugs
LY4268989
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2026-05-07_015809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-07_015809.